PhaseBio Pharmaceuticals Inc

PhaseBio Pharmaceuticals — Q1 2022 Earnings Presentation

32 slides from PhaseBio Pharmaceuticals's earnings presentation, May 16, 2022

  1. Slide 1: Corporate Overview

    Corporate Overview May 2022 PhaseBio

  2. Slide 2: Forward-looking statements

    This presentation includes forward-looking statements. All statements contained in this presentation other than statements of historical facts, including statements regarding future results of operations and financial position of PhaseBio Pharmaceuticals, Inc. (“we,” “us” or “our”), our business str

  3. Slide 3: Therapeutic Focus and Company Overview

    Therapeutic Focus Clinical-stage biopharma company focused on the development and commercialization of novel therapies to treat cardiovascular diseases Product Candidates Bentracimab (PB2452) Novel agent in Phase 3 development for immediate and sustained reversal of ticagrelor, the preferred antipla

  4. Slide 4: A Clinical Stage, Cardiovascular Focused Biopharmaceutical Company

    Program Pre-Clinical Phase 1 Phase 2 Phase 3 Commercial Rights Upcoming Milestone Target2 Bentracimab Reversal of Ticagrelor Antiplatelet Activity Early Q4 2022 Planned BLA submission PB6440 Resistant Hypertension 2H 2022 Submit Investigational New Drug application (IND) Partnering Opportunities Pem

  5. Slide 5: Corporate

    ) Corporate

  6. Slide 6: Experienced Management Team

    6 Experienced Management Team JONATHAN MOW Chief Executive Officer SUSAN ARNOLD, PhD SVP Technical Operations GLEN BURKHARDT SVP Human Resources KRIS HANSON SVP & General Counsel JOHN LEE, MD, PhD, FACC Chief Medical Officer JOHN SHARP Chief Financial Officer JONATHAN BIRCHALL Chief Commercial Offic

  7. Slide 7: Q1 2022 Financial Highlights

    • Sub-license revenue: $0.1M • Operating expense: $18.3M R&D: $14.3M SG&A: $4.0M • Loss from operations: ($18.2M) • Net Loss of ($11.1M) or ($0.23) per share, basic and diluted 48.6M shares used for computing Q1 2022 net loss per share • Cash and cash equivalents as of 03/31/2022: $18.7M • Available

  8. Slide 8: Bentracimab (PB2452) Reversal Agent for Ticagrelor

    Bentracimab (PB2452) Reversal Agent for Ticagrelor

  9. Slide 9: P2Y12 Inhibitors: Unmet Need and the Dilemma in Managing Surgical Patients

    Early surgery = Bleed risk P2Y12 Inhibitors: Unmet Need and the Dilemma in Managing Surgical Patients 9 5d - Ticagrelor washout2 Risk of bleeding Risk of thrombosis and procedural delay Bentracimab Later surgery = Thrombosis risk 1. Plavix/clopidogrel Prescribing Information: https://packageinserts.

  10. Slide 10: Bentracimab: Novel Reversal Agent for Brilinta (Ticagrelor)

    Bentracimab 10 • Ticagrelor has proven superior efficacy vs. clopidogrel and a unique reversible binding profile within the oral P2Y12 class Clopidogrel and prasugrel both permanently bind to the receptor and cannot be reversed • Bentracimab is the only specific reversal agent in development for tic

  11. Slide 11: Well-Characterized Mechanism of Reversal of Ticagrelor

    BentracimabBentracimab: Well-Characterized Mechanism of Reversal of Ticagrelor 11 1. 2. 3. 4. 5. ADP binds to P2Y12 receptor causing platelet aggregation Ticagrelor binds to P2Y12, inhibiting ADP-induced platelet aggregation Bentracimab binds to free ticagrelor with very high affinity This is a reve

  12. Slide 12: Clinical

    Clinical

  13. Slide 13: Immediate and Sustained Ticagrelor Reversal in Phase 1, 2A, 2B Trials

    • Received ticagrelor + low-dose aspirin and bentracimab 18 g • Achieved primary endpoint of ticagrelor reversal measured by VerifyNow P2Y12 assay – Statistically significant reduction in % inhibition of PRU within 4 hours; similar extent of reversal to Phase 1 and 2A • Safety profile consistent wit

  14. Slide 14: REVERSE-IT: Bentracimab Pivotal Phase 3 Trial Overview

    bentracimab 14 REVERSE-IT: Bentracimab Pivotal Phase 3 Trial Overview • REVERSE-IT: Rapid and SustainEd ReVERSal of TicagrElor – Intervention Trial • Open-label, single-arm study in patients with uncontrolled major or life-threatening bleeding or who require urgent surgery or invasive procedure • To

  15. Slide 15: REVERSE-IT: Baseline Characteristics

    bentracimab REVERSE-IT: Baseline Characteristics 15https://evidence.nejm.org/doi/pdf/10.1056/EVIDoa2100047

  16. Slide 16: REVERSE-IT: Platelet Reversal

    bentracimab PRU analysis in surgical vs bleeding patients REVERSE-IT: Platelet Reversal 16 0 4 12 24 72 Hr Hr Hr Hr Hr 8 Hr 16 Hr 20 Hr Time post-reversal PR U 100 200 300 400 Overall PRU analysis in all patients (N=150) (N=8) (N=142) https://evidence.nejm.org/doi/pdf/10.1056/EVIDoa2100047

  17. Slide 17: REVERSE-IT: Adjudicated Surgical and Bleeding Hemostasis

    bentracimab REVERSE-IT: Adjudicated Surgical and Bleeding Hemostasis 17 Adjudicated and Investigator-Reported Surgical Outcomes https://evidence.nejm.org/doi/pdf/10.1056/EVIDoa2100047 Adjudicated and Investigator-Reported Bleeding Outcomes

  18. Slide 18: REVERSE-IT: No Platelet Rebound Activity and No Thrombotic Events

    bentracimab P-selectin in surgical and bleeding patients Mean platelet volume in surgical and bleeding patientsEffect of Bentracimab Treatment on P- Selectin and Mean Platelet Volume (MPV). Soluble P-selectin and MPV were measured pre-dose and at multiple timepoints post-initiation of bentracimab tr

  19. Slide 19: Regulatory

    ) Regulatory

  20. Slide 20: Bentracimab Pre-BLA Meeting Summary

    Bentracimab Pre-BLA Meeting Summary 20 • Type B pre biologics license application (pre-BLA) meeting held in April 2022 • PhaseBio proposed plans to submit a BLA with data from a total of 25-30 patients with uncontrolled bleeding, together with data from the fully completed surgical cohort, to suppor

  21. Slide 21: Bentracimab Development Program

    Bentracimab Development Program 21 2019 2020 2021 2022 2023 Phase 2B: 50-80 year old volunteers CompletedPhase 2APhase 1 NEJM FDA Breakthrough Therapy FDA EOP1 EMA PRIME Designation N=200, 150 randomized to receive bentracimab N=150, major bleeding + urgent surgery patients Final N=200 PMC Completio

  22. Slide 22: Bentracimab Opportunity for Accelerated/Conditional Approval

    Bentracimab Opportunity for Accelerated/Conditional Approval 22 Planned Approval Packages Based on Phase 3 - Interim Analysis • Initial BLA/MAA filing package based on a minimum safety requirement of at least 100 Phase 3 patients • US: Accelerated (Based on biomarker) • EU: Conditional (Based on int

  23. Slide 23: Commercial

    ) Commercial

  24. Slide 24: Expect Continued Long-Term Rx Growth of Ticagrelor

    Bentracimab Expect Continued Long-Term Rx Growth of Ticagrelor Bentracimab approval has the potential to drive continued positive momentum • Brilinta/Brilique sales in 2021 were approximately $1.5B Pandemic impact dampened 2020 and 2021 growth • In February 2019, Brilinta Phase 3 THEMIS1 trial met p

  25. Slide 25: US Patients on P2Y12 Inhibitors: Potential for Ticagrelor Growth

    BentracimabUS Patients on P2Y12 Inhibitors: Potential for Significant Long-Term Ticagrelor Patient Growth 25 0.4 3.8 0.2 2.02.2 0.2 Clopidogrel Prasugrel Ticagrelor US Patients on P2Y12 Inhibitors (millions) 2019 2029 (est.) Continued AZ Promotion Bentracimab Launch Brilinta Patent Expiry Potential

  26. Slide 26: Patient Opportunity Implies $1-2B Addressable Market

    Bentracimab Patient Opportunity (2019) Implies $1-2B* Addressable Market 439,1361 ticagrelor pts/year 4.46M1 total P2Y12 pts/year CABG, coronary artery bypass graft 91,833 (21%5) 26 Inpatient Urgent Surgery3 26,452 (6%5) Inpatient Semi-Elective Surgery4, 48,399 (11%5) ICH 1,698GI 6,623 Trauma 3,396

  27. Slide 27: Increased Mortality and Health-System Costs Associated with Bleeding

    Increased Mortality and Health-System Costs Associated with Bleeding from Open Surgical Procedures Highlight Opportunity for Bentracimab 27 *All charges by the hospital for the inpatient episode – includes drugs, devices, professional fees, room and board etc. ‘Bleed’ = Moderate to Severe Bleeding i

  28. Slide 28: PB6440 Aldosterone Synthase Inhibitor for Resistant Hypertension

    PB6440 Aldosterone Synthase Inhibitor for Resistant Hypertension

  29. Slide 29: PB6440 for Resistant Hypertension

    PB6440 PB6440 for Resistant Hypertension • Upwards of 10 million patients in the United States have resistant hypertension and are at risk for serious, costly medical consequences (stroke, heart attack, kidney failure, etc.)1 • Physicians currently prescribe numerous combinations of antihypertensive

  30. Slide 30: PB6440: A Promising CYP11B2 Inhibitor

    PB6440: A Promising CYP11B2 Inhibitor 30 Characteristics Of PB6440 High in vitro selectivity for CYP11B2 over CYP11B1 High in vitro selectivity for CYP11B2 over drug metabolizing and other steroidal CYPs High oral bioavailability Long half-life in vivo consistent with once-daily dosing Oral PK and s

  31. Slide 31: PB6440 Is Highly Selective for Aldosterone Synthase (CYP11B2)

    PB6440 CYP11B Potency and Selectivity (IC50, μM) Human Monkey CYP11B2 CYP11B1# Selectivity CYP11B2 CYP11B1 Selectivity PB6440 0.024 4.859 202 0.016 5.802 363 LCI699* 0.0007 0.013 19 0.016 0.059 3.7 PB6440 Is Highly Selective for Aldosterone Synthase (CYP11B2) Selectivity and Potency Demonstrated in

  32. Slide 32: Resistant Hypertension (rHTN): Large Market Opportunity

    Resistant Hypertension (rHTN)1: Hypertensive patient on three or more antihypertensive medications and still above goal 32 Large market opportunity2 • ~75M hypertensives in the US • ~55M diagnosed and treated • ~10-15M resistant to treatment • Other potential indications include kidney disease, hear

PhaseBio Pharmaceuticals — Q1 2022 Earnings Presentation on 6ix